WEST

End of Result Set

Generate Collection Print

L5: Entry 1 of 1 File: USPT Sep 12, 2000

DOCUMENT-IDENTIFIER: US 6117985 A
TITLE: Antibody compositions for preparing enriched cell preparations

Detailed Description Paragraph Right (7):
Tumor cells which may be enriched in a sample using the antibody compositions and processes described herein include non-hematopoietic tumor cells which do not express hematopoietic lineage markers. Non-hematopoietic tumors include epithelial cancers of the bronchi, mammary ducts, gastrointestinal tract, reproductive system and urogenital tract such as carcinomas of the lung, breast, colon, prostate, bladder, ovary, endometrium, cervix, pancreas, oesophagus, small bowel, rectum, uterus, stomach, larynx, skin and vagina.

Detailed Description Paragraph Right (42):
In one embodiment, the tumor cells are metastatic tumor cells derived from epithelial cancers of the bronchi, mammary ducts, reproductive system, gastrointestinal tract and urogenital tract such as lung carcinoma, breast carcinoma, colon carcinoma, prostate carcinoma and bladder carcinoma.

CLAIMS:

9. A process according to claim 8 wherein the epithelial cancer is selected from the group consisting of lung carcinoma, breast carcinoma, colon carcinoma, prostate carcinoma and bladder carcinoma.

WEST

End of Result Set

Generate Collection Print

L5: Entry 1 of 1 File: USPT Sep 12, 2000

US-PAT-NO: 6117985
DOCUMENT-IDENTIFIER: US 6117985 A

TITLE: Antibody compositions for preparing enriched cell preparations

DATE-ISSUED: September 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thomas; Terry	Vancouver			CAX
Lansdorp; Peter	Vancouver			CAX

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Stemcell Technologies Inc.	Vancouver			CAX	03

APPL-NO: 9/ 088227 [PALM]
DATE FILED: June 1, 1998

PARENT-CASE:
This is a continuation-in-part of U.S. patent application Ser. No. 08/566,295, filed Dec. 1, 1995, which is a continuation-in-part of U.S. patent application Ser. No. 08/491,175, filed Jun. 16, 1995, now U.S. Pat. No. 5,877,299 that issued on Mar. 2, 1999 both of which are incorporated herein by reference in their entirety.

INT-CL: [7] A61 K 39/395, A61 K 35/12, A01 N 1/02

US-CL-ISSUED: 530/413; 435/2, 435/372, 530/388.73, 530/388.75, 530/388.7, 424/143.1, 424/145.1, 424/153.1, 424/155.1
US-CL-CURRENT: 530/413; 424/143.1, 424/145.1, 424/153.1, 424/155.1, 435/2, 435/372, 530/388.7, 530/388.73, 530/388.75

FIELD-OF-SEARCH: 530/413, 530/388.73, 530/388.75, 530/388.7, 435/2, 435/372, 424/143.1, 424/144.1, 424/153.1, 424/155.1, 424/277.1

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected Search ALL

WEST

End of Result Set

Generate Collection Print

L4: Entry 1 of 1 File: USPT Sep 12, 2000

DOCUMENT-IDENTIFIER: US 6117985 A
TITLE: Antibody compositions for preparing enriched cell preparations

Brief Summary Paragraph Right (21):
The present invention also includes an antibody composition to enrich for hematopoietic stem cells and progenitor cells and to remove non-hematopoietic tumor cells. In such an embodiment, the composition also includes antibodies specific for non-hematopoietic antigens expressed on tumor cells, such as antibodies against antigens expressed on the surface of breast and lung carcinoma and neuroblastoma cells. Accordingly, the present invention provides an antibody composition to enrich for hematopoietic stem cells and progenitor cells and to remove tumor cells comprising antibodies specific for glycophorin A, CD3, CD24, CD 16, CD14 and an antigen present on the tumor cells. The antigens on the tumor cells is preferably a non-hematopoietic antigen expressed on the tumor cells.

Drawing Description Paragraph Right (7):
FIG. 4A shows a Fluorescence Activated Cell Sorting (FACS) profile of peripheral blood seeded with CAMA Breast carcinoma cell line before enrichment using the tumor enrichment composition.

Drawing Description Paragraph Right (8):
FIG. 4B shows a Fluorescence Activated Cell Sorting (FACS) profile of peripheral blood seeded with CAMA Breast carcinoma cell line after enrichment using the tumor enrichment composition.

Detailed Description Paragraph Right (5):
Tumor cells which may be removed from a sample using the antibody compositions and processes described herein include tumor cells which have non-hematopoietic antigens or markers expressed on their surfaces i.e. antigens that distinguish the tumor cells from hematopoietic progenitor cells and stem cells. For example, specific markers have been found to be expressed on tumor cells such as breast and lung carcinoma, and neuroblastoma. Table 4 lists specific examples of antibodies which recognize non-hematopoietic antigens expressed on tumor cells.

Detailed Description Paragraph Right (7):
Tumor cells which may be enriched in a sample using the antibody compositions and processes described herein include non-hematopoietic tumor cells which do not express hematopoietic lineage markers. Non-hematopoietic tumors include epithelial cancers of the bronchi, mammary ducts, gastrointestinal tract, reproductive system and urogenital tract such as carcinomas of the lung, breast, colon, prostate, bladder, ovary, endometrium, cervix, pancreas, oesophagus, small bowel, rectum, uterus, stomach, larynx, skin and vagina.

Detailed Description Paragraph Right (13):
The present invention also includes an antibody composition for enriching and recovering hematopoietic stem cells and progenitor cells and depleting non-hematopoietic tumor cells. In such an embodiment, the composition also includes antibodies specific for non-hematopoietic antigens expressed on tumor cells, such as antibodies against antigens expressed on the surface of breast and lung carcinoma and neuroblastoma cells. The antibodies to the tumor antigens may be obtained from commercial sources or prepared using techniques known in the art. Preferably, the antibodies specific for non-hematopoietic antigens are specific for antigens expressed on breast and lung carcinoma and neuroblastoma cells, for example a shown in Table 4.